Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma

Calogero Camma', Giuseppe Cabibbo, Salvatore Petta, Antonio Craxi, Alberto Masotto, Andrea Olivani, Gian Lodovico Rapaccini, Fabio Marra, Antonio Gasbarrini, Maria Di Marco, Francesca Ciccarese, Giulia Negrini, Andrea Mega, Marco Zoli, Gianluca Svegliati-Baroni, Laura Bucci, Francesco Giuseppe Foschi, Gian Lodovico Rapaccini, Gian Lodovico Rapaccini, Roberto VirdoneLuisa Benvegnù, Franco Borzio, Filomena Morisco, Antonio Colecchia, Gerardo Nardone, Fabio Farinati, Franco Trevisani, Eugenio Caturelli, Rodolfo Sacco, Edoardo G. Giannini, Marcello Persico, Marco Barbara, Simona Attardo

Risultato della ricerca: Articlepeer review

42 Citazioni (Scopus)

Abstract

Background & Aims Assessment of long-term outcome is required in hepatitis C virus (HCV)-infected patients with cirrhosis, who have been successfully treated for Barcelona Clinic Liver Cancer (BCLC) stage A hepatocellular carcinoma (HCC). However, problems arise due to the lack of models accounting for early changes during follow-up. The aim of this study was to estimate the impact of early events (HCC recurrence or hepatic decompensation within 12 months of complete radiological response) on 5-year overall survival (OS) in a large cohort of patients with HCV and cirrhosis, successfully treated HCC. Methods A total of 328 consecutive Caucasian patients with HCV-related cirrhosis and BCLC stage 0/A HCC who had complete radiological response after curative resection or thermal ablation were prospectively recruited to this study. Primary endpoint of the study was 5-year OS. Independent baseline and time-dependent predictors of 5-year OS were identified by Cox model. Results The observed 5-year survival rate was 44%. The observed HCC early recurrence and early hepatic decompensation rate were 21% and 10%, respectively. Early hepatic decompensation (Hazard Ratio [HR] 7.52; 95% confidence intervals (CI): 1.23â13.48) and HCC early recurrence as time-dependent covariates (HR 2.50; 95%CI: 1.23â5.05), presence of esophageal varices at baseline (HR 1.66; 95% CI: 1.02â2.70) and age (HR 1.04; 95% CI: 1.02â1.07) were significantly associated with the 5-year OS. Conclusion Survival in HCV-infected patients with cirrhosis and successfully treated HCC is influenced by early hepatic decompensation. Our study indirectly suggests that direct-acting antiviral agents could improve OS of HCC patients through long-term preservation of liver function, resulting in a lower cirrhosis-related mortality and a greater change of receiving curative treatments. Lay summary Survival in hepatitis C virus (HCV) infected patients with cirrhosis and successfully treated hepatocellular carcinoma (HCC), is mainly influenced by early hepatic decompensation. HCV eradication after treatment with new direct-acting antiviral agents could improve overall survival of HCC patients through long-term preservation of liver function.
Lingua originaleEnglish
pagine (da-a)65-71
Numero di pagine7
RivistaJournal of Hepatology
Volume67
Stato di pubblicazionePublished - 2017

All Science Journal Classification (ASJC) codes

  • Hepatology

Fingerprint Entra nei temi di ricerca di 'Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma'. Insieme formano una fingerprint unica.

Cita questo